A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
A recent CME course using Facebook Live generated 34,000 views and 600 comments.
The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.
Rising healthcare costs, the need for team health delivery and enhanced teamwork, and empowered consumers have all played a role.
One critical aspect of oncology drugmakers' business remains firmly rooted in the past. That's customer experience.
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion
We need to consider that not every expenditure is beneficial to patients: perhaps that Super Bowl commercial or that sales meeting in Maui may not be in their best interest.
The main accreditation body for CME activities traded barbs with an academic critic over courses designed to enlighten doctors about hypoactive sexual desire disorder.
Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
New rules will require manufacturers to report some indirect payments made to physicians for CME activities.
Pharma's efforts to evolve restrictions about off-label marketing move forward.
The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.
Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME
The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.
The draft would allow drugmakers to share off-label economic data with payers, a practice that until now has been considered taboo, and require the FDA to assess patient experience data in regulatory decisions, in addition to boosting funding for the NIH.
After a wave of feedback, the accreditor has deferred a ban on use of corporate logos in disclosures of commercial support.
The accreditor wants comments on its new accreditation plan, but a new commendation proposal is yet to come.
Pew Charitable Trust's proposed conflict of interest guidelines could mean even less face time for sales reps and less industry money for CME programs.
The publisher says the latest release enriches the CE experience through direct links to Nursing Advisor content.
The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.
Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.
Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.
Pharma's med-ed cut was its fifth in a row. But other income surged, filling the void as the funding picture for CME continued to even out.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The estimated cost savings for only 10% of participants changing their practice is somewhere in the million-dollar range, according to a study.
A CME activity was associated with increased testing that could head off neuropathy in patients with type 2 diabetes.
Boehringer Ingelheim and Eli Lilly rolled out a pre-launch SGLT campaign that breaks ranks with branding for J&J's SGLT2 inhibitor Invokana.